Manufacturing Process Development for Metabolically Reprogrammed Tumor-Infiltrating Lymphocytes
Dr. Marcus Butler, University Health Network
Approved October 2024 | Project Value $742,250 | Partners 1 | $367,250 from BioCanRx
Approved October 2024 | Project Value $742,250 | Partners 1 | $367,250 from BioCanRx
Eligible cancers: Myeloma
Keywords: Cell therapy, Tumor-infiltrating lymphocytes, Cell metabolism, Manufacturing, Process Development
Advancing GMP-Compliant Lentiviral Vector Manufacturing Enhancers for Cost-Effective Production of Anti-Cancer Cell Therapies
Dr. JS Diallo, Ottawa Hospital Research Institute
Approved October 2024 | Project Value $1,521,129 | Partners 1 | $732,783 from BioCanRx
Approved October 2024 | Project Value $1,521,129 | Partners 1 | $732,783 from BioCanRx
Keywords: Bioprocess, Lentivirus, Biomanufacturing, Viral sensitizers, Analytical Assays,
Biotherapeutics, Formulation Development, GMP manufacturing
Biotherapeutics, Formulation Development, GMP manufacturing
Accelerating the Clinical Translation of a Virally Programmed Exosome-Based Cancer Vaccine
Dr. Carolina Ilkow, Ottawa Hospital Research Institute
Approved October 2024 | Project Value $1,735,193 | Partners 4 | $749,901 from BioCanRx
Approved October 2024 | Project Value $1,735,193 | Partners 4 | $749,901 from BioCanRx
Eligible cancers: TBD
Keywords: Cancer Vaccines, Oncolytic Viruses, Exosomes, Tumour, Explants, Biodistribution;, Biomanufacturing, Toxicity Study
CTA submission for TITAN-01 (Thymic Treg Immune Therapy AgaiNst GVHD)
Dr. Megan Levings, University of British Columbria
Approved October 2024 | Project Value $1,898,364 | Partners 5 | $750,000 from BioCanRx
Approved October 2024 | Project Value $1,898,364 | Partners 5 | $750,000 from BioCanRx
Eligible cancers: Blood cancer
Keywords: Blood cancer, Graft versus host disease, Regulatory T cell therapy, Biomanufacturing, Clinical Trial Application, Immunotherapy, Allogeneic cell therapy
Personalized CAR T-cell therapy for a patient with a rare sarcoma
Dr. Douglas Mahoney, University of Calgary
April 1 2022 | Project value $948,048 | 3 partners | $125,000 from BioCanRx
April 1 2022 | Project value $948,048 | 3 partners | $125,000 from BioCanRx
Eligible cancers: Alveolar Soft Part Sarcoma (ASPS)
Development of Supporting Analytical Assays and Regulatory Compliance Package for Viral Sensitizer Technology Commercialization
Dr. Jean-Simon Diallo, Ottawa Hospital Research Insitute
Approved July 1, 2020 | Project value $1,020,000 | 1 partners | $449,829 from BioCanRx
Approved July 1, 2020 | Project value $1,020,000 | 1 partners | $449,829 from BioCanRx
Eligible cancers: Hematologic
Enabling a Phase I/II Multicenter Clinical Trial of a Novel Single Domain (sd)CD-22-specific Camelid-derived Chimeric Antigen Receptor (CAR) T-cell Therapy
Dr. Kevin Hay, BC Cancer Agency
Approved April 1, 2020 | Project value $950,000 | 2 partners | $450,000 from BioCanRx
Approved April 1, 2020 | Project value $950,000 | 2 partners | $450,000 from BioCanRx
Eligible cancers: Non-Hodgkin’s lymphoma; Acute lymphoblastic leukemia
Development of a Virally Programmed Exosome-based Cancer Vaccine Platform
Dr. Carolina Ilkow, Ottawa Hospital Research Institute
Approved July 1, 2020 | Project value $2,310,000 | 6 partners | $616,500 from BioCanRx
Approved July 1, 2020 | Project value $2,310,000 | 6 partners | $616,500 from BioCanRx
Eligible cancers: All
Recombinant TCRs to Target KRAS Hotspot Mutations in Pancreatic Cancer
Dr. Robert Holt, BC Cancer Agency
Approved October 1, 2020 | Project value $950,000 | 2 partners | $450,000 from BioCanRx
Approved October 1, 2020 | Project value $950,000 | 2 partners | $450,000 from BioCanRx
Eligible cancers: Pancreatic
Clinical Trial Enabling Studies for Multi-targeted Chimeric Antigen Receptor Therapeutics for the Treatment of B-Cell Malignancies
Dr. Scott McComb, University of Ottawa
Approved October 1, 2020 | Project value $950,000 | 3 partners | $450,000 from BioCanRx
Approved October 1, 2020 | Project value $950,000 | 3 partners | $450,000 from BioCanRx
Eligible cancers: B-cell Leukemia
First in Human ThINKK Adoptive Immunotherapy to Prevent Leukemia and Neuroblastoma Relapse: GMP-manufacturing and Phase I Clinical Trial
Dr. Michel Duval, CHU Sainte-Justine
Approved July 1, 2020 | Project value $940,500 | 2 partners | $445,500 from BioCanRx
Approved July 1, 2020 | Project value $940,500 | 2 partners | $445,500 from BioCanRx
Eligible cancers: Acute leukemia; neuroblastome
Development of a Novel, Phase 1-Ready, Viro-Immunotherapeutic
Dr. John Bell, Ottawa Hospital Research Institute
Approved April 23, 2018 | Project value $1,940,978 | 4 partners | $375,000 from BioCanRx
Approved April 23, 2018 | Project value $1,940,978 | 4 partners | $375,000 from BioCanRx
Eligible cancers: All cancers
Keywords: Oncolytic Vaccinia, iCELLis, oncolytic viruses, immune stimulation
Keywords: Oncolytic Vaccinia, iCELLis, oncolytic viruses, immune stimulation
Advanced preclinical development of AVID200: Preparing for immunotherapy clinical trials
Dr. James Koropatnick, Lawson Health Research Institute, University of Western Ontario
Approved January 31, 2018 | Project value $1,927,386 | 1 partner | $675,500 from BioCanRx
Approved January 31, 2018 | Project value $1,927,386 | 1 partner | $675,500 from BioCanRx
Eligible cancers: solid tumors and myelofibrosis
Keywords: AVID200, anti-TGFß
Keywords: AVID200, anti-TGFß
In vivo human therapeutic cell tracking using a [19F]-perfluorocarbon cellular MRI contrast agent: Phase I feasibility and preliminary safety trial
Dr. Gregory Dekaban, Robarts Research, McMaster University
Approved October 14, 2016 | Project value $91,264 | 3 partners | $43,500 from BioCanRx
Approved October 14, 2016 | Project value $91,264 | 3 partners | $43,500 from BioCanRx
Eligible cancers: all cancers that use virus antigens
Keywords: antigen presenting cells, Cell-based cancer vaccine immunotherapy
Keywords: antigen presenting cells, Cell-based cancer vaccine immunotherapy
Oncolytic vaccinia virus for bladder cancer treatment: preparation for a phase I/II trial
Dr. David Evans, University of Alberta
Approved January 17, 2017 | Project value $2.56 M | 2 partners | $226,054 from BioCanRx
Approved January 17, 2017 | Project value $2.56 M | 2 partners | $226,054 from BioCanRx
Eligible cancers: bladder cancer (non-muscle invasive bladder cancer)
Keywords: oncolytic vaccinia virus
Keywords: oncolytic vaccinia virus
Capacity building for Chimeric Antigen Receptor (CAR)-modified T cell therapies in Canada
Dr. Rob Holt, BC Cancer Agency, University of British Colombia
Approved January 17, 2017 | Project value $2.66 M | 3 partners | $1,344,376 from BioCanRx
Approved January 17, 2017 | Project value $2.66 M | 3 partners | $1,344,376 from BioCanRx
Eligible cancers: blood cancers
Keywords: CAR-T cells, CD19
Keywords: CAR-T cells, CD19
Garbage to Gold: expansion of Therapeutic Regulatory T Cells from discarded thymus
Dr. Megan Levings, BC Children’s Hospital Research Institute
Approved January 17, 2017 | Project value $1.01 M | 7 partners | $275,659 from BioCanRx
Approved January 17, 2017 | Project value $1.01 M | 7 partners | $275,659 from BioCanRx
Eligible cancers: hematologic malignancies
Keywords: regulatory T cell (Treg), graph-versus host disease
Keywords: regulatory T cell (Treg), graph-versus host disease
Adoptive T cell therapy targeting patient-specific driver mutations in lymphoma
Dr. Brad Nelson, BC Cancer Agency, University of British Colombia
Approved October 14, 2016 | Project value $734,686 | 3 partners | $358,186 from BioCanRx
Approved October 14, 2016 | Project value $734,686 | 3 partners | $358,186 from BioCanRx
Eligible cancers: follicular lymphoma
Keywords: adoptive cell therapy, T cells, autologous peripheral blood mononuclear cells, CD8+
Keywords: adoptive cell therapy, T cells, autologous peripheral blood mononuclear cells, CD8+
Development of predictive companion biomarkers and therapeutic monitoring for hypermutant cancers to immune checkpoint inhibition
Dr. Uri Tabori, The Hospital for Sick Children, University of Toronto
Approved October 14, 2016 | Project value $1,490,253 | 1 partners | $744,996 from BioCanRx
Approved October 14, 2016 | Project value $1,490,253 | 1 partners | $744,996 from BioCanRx
Eligible cancers: hyper-mutant cancers
Keywords: biomarkers, PD-1 blokade
Keywords: biomarkers, PD-1 blokade
COMBINING ONCOLYTIC VACCINE THERAPY WITH ADOPTIVE CELL THERAPY TO TARGET CANCERS EXPRESSING MAGE-A3
Dr. Yonhong Wan, McMaster University
Approved June 10, 2015 | Project value $695,181 | 5 partners | $263,181 from BioCanRx
Approved June 10, 2015 | Project value $695,181 | 5 partners | $263,181 from BioCanRx
Eligible cancers: anal, bladder, breast, cervical, colon, esophageal, kidney, liver, lung, melanoma, mouth, ovarian, pancreatic, prostate, stomach, uterine
Keywords: oncolytic virus, oncolytic vaccine, adoptive cell therapy, autologous T cells, adenovirus vaccine, Maraba oncolytic virus, AdMA3, MG1MA3, MAGE-A3 antigen
Keywords: oncolytic virus, oncolytic vaccine, adoptive cell therapy, autologous T cells, adenovirus vaccine, Maraba oncolytic virus, AdMA3, MG1MA3, MAGE-A3 antigen
ADVANCED PRECLINICAL DEVELOPMENT OF THE ONCOLYTIC VACCINE PLATFORM TO PREPARE REQUIREMENTS FOR A CLINICAL TRIAL OF PATIENTS WITH HPV-ASSOCIATED CANCERS
Dr. Brian Lichty, McMaster University
Approved June 10, 2015 | Project value $1.027 million | 4 partners | $462,264 from BioCanRx
Approved June 10, 2015 | Project value $1.027 million | 4 partners | $462,264 from BioCanRx
Eligible cancers: anal, cervical, esophageal, larynx, oral
Keywords: oncolytic virus, oncolytic vaccine, adenovirus vaccine, Maraba oncolytic virus, HPV, human papilloma virus, AdHPV, MG1HPV, HPV-E6/E7 antigen
Keywords: oncolytic virus, oncolytic vaccine, adenovirus vaccine, Maraba oncolytic virus, HPV, human papilloma virus, AdHPV, MG1HPV, HPV-E6/E7 antigen
DEVELOPMENT OF IMMUNE REGULATING ANTIBODIES FOR USE IN COMPANION ANIMAL CLINICAL TRIALS
Dr. Jason Moffat, University of Toronto
Approved June 10, 2015 | Project value $1.56M | 7 partner | $708,893 from BioCanRx
Approved June 10, 2015 | Project value $1.56M | 7 partner | $708,893 from BioCanRx
Eligible cancers: melanoma
Keywords: synthetic antibodies, immune checkpoint inhibitors
Keywords: synthetic antibodies, immune checkpoint inhibitors
DEVELOPMENT OF ANTIBODY-BASED PLATFORMS THAT SPECIFICALLY TARGET CANCER CELLS
Dr. Steven Jones, BC Cancer Agency, University of British Columbia, Simon Fraser University
Approved September 29, 2015 | Project value $2.25M | 1 partner | $749,555 from BioCanRx
Approved September 29, 2015 | Project value $2.25M | 1 partner | $749,555 from BioCanRx
Eligible cancers: to be determined by study
Keywords: antibodies, antibody-drug conjugates, ADCs, theranostics, radioimmunotherapy, radio-immuno conjugate, diagnostic imaging, pancratistatin ADCs
Keywords: antibodies, antibody-drug conjugates, ADCs, theranostics, radioimmunotherapy, radio-immuno conjugate, diagnostic imaging, pancratistatin ADCs
DEVELOPING T CELLS THAT TARGET ANTIGENS SPECIFIC TO LYMPHOID CANCERS
Dr. Denis Claude Roy, Hôpital Maisonneuve-Rosemont, Université de Montréal
Dr. Claude Perreault, Hôpital Maisonneuve-Rosemont, Université de Montréal
Approved September 29, 2015 | Project value $729,875 | 3 partners | $299,875 from BioCanRx
Dr. Claude Perreault, Hôpital Maisonneuve-Rosemont, Université de Montréal
Approved September 29, 2015 | Project value $729,875 | 3 partners | $299,875 from BioCanRx
Eligible cancers: chronic lymphocytic leukemia (CLL), lymphoid hematologic malignancies, non-Hodgkin’s lymphoma,
Keywords: adoptive cell therapy, minor histocompatibility antigens, MiHAs
Keywords: adoptive cell therapy, minor histocompatibility antigens, MiHAs
